Atlas Trials

An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings

Clinical trial NCT05362149 · COMPLETED

Trial details

NCT number
NCT05362149
Sponsor
Bayer
Status
COMPLETED
Study type
OBSERVATIONAL
Non-metastatic Castration-resistant Prostate Cancer
Start date
2022-04-04
Primary completion
2023-06-30
Enrollment
870

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.